 ?您的位置：對(duì)照品 > 標(biāo)準(zhǔn)物質(zhì) > 農(nóng)殘標(biāo)準(zhǔn)物質(zhì) > |
|
|
|
| 產(chǎn)品基本信息 |
|
| 產(chǎn)品編號(hào)：L175813 |
| 產(chǎn)品名稱：Lapatinib Ditosylate Monohydrate |
| 產(chǎn)品CAS：388082-78-8 |
| 規(guī)格含量：2mg |
| 產(chǎn)品價(jià)格：面議 |
| 聯(lián)系我們: |
 |
|
 |
|
|
| 產(chǎn)品詳細(xì)介紹 |
| 標(biāo)準(zhǔn)品編號(hào): |
L175813 |
| 名稱: |
Lapatinib Ditosylate Monohydrate |
| 別名: |
N-?[3-?chloro-?4-?[(3-?fluorophenyl)?methoxy]?phenyl]?-?6-?[5-?[[[2-?(methylsulfonyl)?ethyl]?amino]?methyl]?-?2-?furanyl]?-?4-?Quinazolinamine 4-?methylbenzenesulfona?te hydrate; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine bis(4-methylbenzenesulfonate) monohydrate |
| CAS號(hào): |
388082-78-8 |
| 分子式: |
C??H??ClFN?O?S • 2(C?H?O?S) • H?O |
| 分子量: |
943.48 |
| 種類: |
Standards; Pharmaceutical/API Drug Impurities/Metabolites; |
| 應(yīng)用: |
Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor. |
| 參考文獻(xiàn) |
|
|
|
|
|
|
